21 August 2018 - - China-based pharmaceutical and medical device open-access capability and technology platform company WuXi AppTec's Research Service Division and Canadian biotechnology company Cyclica have launched a multi-phase collaboration to advance drug discovery programmes by driving insights into small molecule polypharmacology, while further evolving Cyclica's biophysics and AI-augmented platform, the companies said.

Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica's cloud-based proteome Ligand Express screening platform to investigate the off-target profiles of small molecules.

It will also apply Cyclica's novel and proprietary advanced AI technology to create predictive models for ADMET properties, and support the testing and optimisation of Cyclica's next generation AI-based de novo drug design technology.

Cyclica is a Toronto-based biotechnology company that is driving drug discovery by empowering scientists in pharma with an integrated cloud-based and AI-augmented platform that enhances how they design, screen and personalise medicines.